PhaseBio details dollars in AstraZeneca deal as it rolls out a plan for $86M-plus IPO

It turns out the $34 million Series D PhaseBio announced just days ago was a prelude to a bigger story: With its newly honed orphan disease-focused strategy, the biotech is angling for an IPO worth at least $86 million.